Markets

Pipeline Progress at GlaxoSmithKline - Analyst Blog

An image of a compass on a chart
Credit: Shutterstock photo

GlaxoSmithKline plc ( GSK ) announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod.

Glaxo is evaluating the efficacy of losmapimod in patients suffering from acute coronary syndrome.

The randomized double-blind, placebo-controlled study will assess if losmapimod can reduce the risk of a subsequent cardiac event when administered orally twice a day for a period of three months, immediately after patients show symptoms of a coronary heart disease.

The primary efficacy objective of the trial is the composite measure of adjudicated major adverse cardiovascular events, comprising the time to first occurrence of cardiovascular death, myocardial infarction, or severe recurrent ischemia requiring urgent coronary artery revascularization.

Glaxo is conducting the study in collaboration with the TIMI Study Group, Brigham and Women's Hospital, Boston, MA.

We note that Glaxo suffered a pipeline setback last month when its other cardiovascular candidate darapladib failed to meet the primary objective in a phase III study. Glaxo had announced disappointing top-line data from the first study (STABILITY) on darapladib as well in Nov 2013.

Hence, we expect investor focus to be on updates from LATITUDE-TIMI 60 study. The successful development and commercialization of losmapimod will bode well for Glaxo given the recent setbacks on the other candidate. Moreover, Glaxo's top line is under pressure with sales of many of its key products dwindling due to generic competition. Consequently, Glaxo is relying heavily on the success of its pipeline candidates to boost growth in the coming years.

Glaxo carries a Zacks Rank #3 (Hold). Right now, stocks like Allergan ( AGN ), Gilead Sciences ( GILD ) and Alexion Pharmaceuticals ( ALXN ) look better placed in the healthcare space. While Allergan and Gilead are Zacks Rank #1 (Strong Buy) stocks, Alexion holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD GSK ALXN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More